Clinical Trials Logo
  1. Home
  2. SCLC
  3. NCT00046787
  4. Details
NCT00046787 Clinical Trial

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

SCLC Clinical Trial

Official title:
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00046787
Other study ID # 110-12
Secondary ID
Status Completed
Phase Phase 2
First received October 3, 2002
Last updated October 18, 2011
Start date September 2002
Est. completion date February 2003

Study information
Verified date October 2011
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.

Recruitment information / eligibility
Status Completed
Enrollment 47
Est. completion date February 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Confirmed recurrent small cell lung cancer.

- One prior treatment of chemotherapy.

- At least three weeks since last chemotherapy treatment and recovery from any related side effects.

- At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects.

- At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan).

- If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable.

Exclusion Criteria:

- Superior vena cava syndrome.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• OSI-211 (Liposomal Lurtotecan)

Locations
Country Name City State
United Kingdom Aberdeen Royal Infirmary Aberdeen
United Kingdom Clatterbridge Centre for Oncology Bebington Wirral
United Kingdom Guys Hospital London
United Kingdom Christie Hospital Manchester
United Kingdom Northern Centre for Cancer Research, Newcastle General Hospital Newcastle-upon-Tyne
United Kingdom Nottingham City Hospital Nottingham Nottinghamshire
United States University of Colorado Health Sciences Center Denver Colorado
United States Baptist Hospital Regional Cancer Ctr. Knoxville Tennessee
United States Vanderbilt Clinical Trials Office Nashville Tennessee
United States Arizona Clinical Research Center, Inc. Tucson Arizona

Sponsors (2)
Lead Sponsor Collaborator
Astellas Pharma Inc OSI Pharmaceuticals

Countries where clinical trial is conducted

United States,  United Kingdom, 

See also
  Status Clinical Trial Phase
Completed NCT05026593 - A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04826341 - A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Phase 1/Phase 2
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Withdrawn NCT04677361 - Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab Early Phase 1
Terminated NCT00522639 - Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation Phase 3
Completed NCT03428607 - Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] Phase 2
Recruiting NCT05546268 - Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Not yet recruiting NCT03244904 - Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment N/A
Completed NCT01713296 - Pazopanib in Relapsed and Refractory Small Cell Lung Cancer Phase 2
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Recruiting NCT05130255 - GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 Phase 1
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Recruiting NCT05879068 - A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC Phase 2
Recruiting NCT04684017 - Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer Phase 2
Completed NCT00346385 - BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT02734004 - A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Phase 1/Phase 2